Fencarol (hifenadina hydrochloride) tablets 50 mg. №30

Description

Fencarol 50 mg Storage
active substance: hyfenadine;

1 tablet contains hyphenadine hydrochloride 50 mg;

excipients: sucrose, potato starch, modified corn starch, calcium stearate.

Fencarol 50 mg Dosage form
Tablets.

Basic physical and chemical properties: flat-cylindrical tablets of white or almost white color, with a facet.

Fencarol 50 mg Pharmacotherapeutic group
Antihistamines for systemic use.

ATC code R06A HZ1.

Pharmacological properties

Pharmacodynamics.

Hifenadine is a derivative of quinuclidylcarbinol, which reduces the effects of histamine on organs and systems. Hifenadine is a competitive H1-receptor blocker. In addition, it activates the enzyme diamine oxidase, which breaks down approximately 30% of endogenous histamine. This explains the effectiveness of hyfenadine in patients insensitive to other antihistamines. Hifenadine does not cross the blood-brain barrier well and has little effect on the deamination of serotonin in the brain, has little effect on monoamine oxidase activity. The antihistamine properties of hyphenadine are related to the presence of a cyclic quinuclidine nucleus in the structure and the distance between the diphenylcarbinol group and the nitrogen atom. Diphenhydramine predominates in antihistaminic activity and duration of action. Hifenadine reduces the toxic effect of histamine, reduces or reduces its bronchoconstrictor effect and spasmodic effect on intestinal smooth muscle, has a moderate antiserotonin and weak cholinolytic effect, well-defined antipruritic and desensitizing properties. Hifenadine weakens the antihypertensive effect of histamine and its effect on capillary permeability, does not directly affect cardiac activity and blood pressure, does not have a protective effect in aconicotine arrhythmias.

Hifenadine does not depress the central nervous system, but with individual hypersensitivity, a weak sedative effect is possible. The drug is slightly lipophilic, and its content in brain tissue is low (less than 0.05), which explains the lack of depressant effect on the central nervous system.

Pharmacokinetics.

Hifenadine is rapidly absorbed from the gastrointestinal tract and within 30 minutes it is detected in body tissues. The maximum concentration is reached in 1 hour.

Metabolites and unchanged proportion of hyfenadine are mainly excreted in the urine, bile and lungs within 48 hours.

Indication
Pollinosis, food and drug allergies, other allergic diseases, acute and chronic urticaria, edema (angioneurotic) Quincke, hay fever, allergic rhinopathy, dermatoses (eczema, psoriasis, neurodermatitis, itchy skin), as well as infectious infections and allergies component.

Contraindication
Hypersensitivity to hyfenadine or to any of the excipients.

Interaction with other medicinal products and other forms of interaction
Fencarol® does not enhance the inhibitory effect of alcohol and hypnotics on the central nervous system, has weak M-cholinoblocking properties, but with reduced gastrointestinal motility, the absorption of slowly absorbed drugs may increase (eg, anticoagulants of indirect action – coumarin).

Features of application
Caution should be exercised when prescribing the drug in severe diseases of the cardiovascular system, gastrointestinal tract and liver.

The drug contains sucrose, which should be considered by patients with diabetes.

Patients with rare hereditary problems of fructose intolerance or sucrase-isomaltase insufficiency should not take this medicine.

Use during pregnancy or breastfeeding.

There are insufficient animal studies to evaluate the effect of the drug on pregnancy.

It is contraindicated to prescribe the drug during the first trimester of pregnancy. The drug is not recommended during the second and third trimesters of pregnancy.

There are no data on the penetration of the drug into breast milk, so the use of Fencarol® is contraindicated during breastfeeding.

Ability to influence the speed of reaction when driving a car or other machinery.

Individuals whose work requires a rapid physical or mental response (drivers) should first establish individual sensitivity (through short-term use) to sedation. If there is hypersensitivity, such persons should be especially careful when using the drug.